(NASDAQ: BBNX) Beta Bionics's forecast annual revenue growth rate of 28.58% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.08%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Beta Bionics's revenue in 2026 is $127,265,000.On average, 16 Wall Street analysts forecast BBNX's revenue for 2026 to be $7,022,050,374, with the lowest BBNX revenue forecast at $6,500,126,531, and the highest BBNX revenue forecast at $7,686,959,603. On average, 16 Wall Street analysts forecast BBNX's revenue for 2027 to be $10,128,584,582, with the lowest BBNX revenue forecast at $9,052,116,656, and the highest BBNX revenue forecast at $10,960,400,707.
In 2028, BBNX is forecast to generate $15,043,367,439 in revenue, with the lowest revenue forecast at $12,739,291,139 and the highest revenue forecast at $19,409,042,919.